317 related articles for article (PubMed ID: 22994780)
1. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
Zhang QC; Jiang SJ; Zhang S; Ma XB
Asian Pac J Cancer Prev; 2012; 13(7):3471-6. PubMed ID: 22994780
[TBL] [Abstract][Full Text] [Related]
2. [Effect of trichostatin A and paclitaxel on the growth and apoptosis of lung adenocarcinoma cell lines].
Zhang S; Wang XA; Zhang QC; Jiang SJ
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):492-6. PubMed ID: 22967465
[TBL] [Abstract][Full Text] [Related]
3. Effect of trichostatin A and paclitaxel on the proliferation and apoptosis of lung adenocarcinoma cells.
Zhang S; Zhang QC; Jiang SJ
Chin Med J (Engl); 2013 Jan; 126(1):129-34. PubMed ID: 23286491
[TBL] [Abstract][Full Text] [Related]
4. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Chen MC; Chen CH; Wang JC; Tsai AC; Liou JP; Pan SL; Teng CM
Cell Death Dis; 2013 Sep; 4(9):e810. PubMed ID: 24052078
[TBL] [Abstract][Full Text] [Related]
5. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
6. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Duo J; Ma Y; Wang G; Han X; Zhang C
DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
[TBL] [Abstract][Full Text] [Related]
7. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
8. [Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells].
Yang YN; Wang Y; Wang XG; Jiang SJ
Ai Zheng; 2008 Aug; 27(8):816-21. PubMed ID: 18710614
[TBL] [Abstract][Full Text] [Related]
9. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
Greve G; Schiffmann I; Pfeifer D; Pantic M; Schüler J; Lübbert M
BMC Cancer; 2015 Dec; 15():947. PubMed ID: 26675484
[TBL] [Abstract][Full Text] [Related]
10. Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line.
Zhang X; Jiang SJ; Shang B; Jiang HJ
Thorac Cancer; 2015 Mar; 6(2):202-8. PubMed ID: 26273359
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Dowdy SC; Jiang S; Zhou XC; Hou X; Jin F; Podratz KC; Jiang SW
Mol Cancer Ther; 2006 Nov; 5(11):2767-76. PubMed ID: 17121923
[TBL] [Abstract][Full Text] [Related]
12. KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Kurtze I; Sonnemann J; Beck JF
Oncol Rep; 2011 Apr; 25(4):1021-9. PubMed ID: 21271222
[TBL] [Abstract][Full Text] [Related]
13. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
[TBL] [Abstract][Full Text] [Related]
14. ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-κB-dependent and Notch-independent mechanism.
Yao J; Qian CJ; Ye B; Zhang X; Liang Y
Life Sci; 2012 Sep; 91(5-6):186-93. PubMed ID: 22781708
[TBL] [Abstract][Full Text] [Related]
15. [Synergistic cytotoxicity effect of histone deacetylase inhibitor combined with paclitaxel on lung cancer cell lines and its mechanism].
Zhang D; Liu CT; Yu XD; Liu Y
Ai Zheng; 2009 Dec; 28(12):1270-6. PubMed ID: 19958621
[TBL] [Abstract][Full Text] [Related]
16. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
17. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Mahaffey CM; Davies AM; Lara PN; Pryde B; Holland W; Mack PC; Gumerlock PH; Gandara DR
Clin Lung Cancer; 2007 Nov; 8(9):548-53. PubMed ID: 18186959
[TBL] [Abstract][Full Text] [Related]
19. [Effects of trichostatin A on human lung cancer cell strains A549].
Zhang D; Liu CT; Yu XD; Liu Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr; 32(2):167-70. PubMed ID: 20450546
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
